- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06643039
Infección por virus respiratorios nosocomiales (NOSOVIRUS)
Infección viral respiratoria adquirida en el hospital: un estudio multicéntrico prospectivo en Francia
Hospital-acquired Viral Respiratory Infections (HAVRI) are associated with substantial burden on health care systems. The prevention and control of these viral infections rely on multiple measures such as hand hygiene or wearing mask. However, vaccination remains the major preventive measure.
To date, data at French national level are insufficient to describe the epidemiology of these infections, including their burden, and the potential protection of patients if vaccination coverage of health care professionals/patients is satisfactory. In addition, better understanding of the clinical characteristics of HAVRI will make it possible to identify potential sources of transmission as soon as possible and to implement appropriate hygiene measures.
We will set up a hospital-based prospective multicenter study in Bordeaux, Paris-Bichat, Dijon and Lyon, involving four inclusion services (geriatrics, internal medicine and transplantation) per hospital.
The main objective of this study is to calculate the incidence rate of hospital-acquired infections for three respiratory viruses; influenza, SARS-CoV-2 and syncytial respiratory virus (SRV), referred to as HARVI, in participating services.
Volunteered health care professionals or hospitalized patients presenting with influenza-like illness (ILI) at admission or during their stay in the participating centers will be eligible to be enrolled during the two inclusion periods: (mid-October 2024 to mid-April 2025 and mid-October 2025 to mid-April 2026).
For each patient/health care professional, a nasopharyngeal swab will be collected. A questionnaire including demographic data, medical history, vaccination, and clinical and biological data of the viral episode will also be completed by the study team. Patients tested positive for one of the viruses studied will be considered "cases" and patients tested negative as "controls".
The collected data will be pseudonymized before statistical analyses. Statistical analyses will consist of calculating incidence rates, attack rates overall and by causative virus and analysis of factors associated with the occurrence of HARVI.
The prospective design of the study will optimize the quality of the collected data (ex. consolidate the documentation of both the clinical picture and vaccination in patients and health care professionals by reducing memory bias) and allow to calculate the incidence rates, the crude and adjusted relative risks of HARVI according to the studied factors, and to describe multiple outcomes (hospitalization in intensive care units, death, etc.) based on the causative virus.
The results of this research project will allow to:
- obtain epidemiological indicators associated with HARVI;
- estimate the impact of HARVI on the prognosis of patients in hospital;
- assess the impact of HARVI on the total length of hospital stay;
- identify risk factors associated with HARVI;
- use the results as an argument for vaccination in order to increase vaccination coverage of healthcare workers.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Philippe VANHEMS, MD, PhD
- Número de teléfono: +33 4 72 11 07 20
- Correo electrónico: Philippe.vanhems@chu-lyon.fr
Copia de seguridad de contactos de estudio
- Nombre: Mitra SAADATIAN-ELAHI
- Número de teléfono: +33 4 72 11 07 18
- Correo electrónico: Mitra.elahi@chu-lyon.fr
Ubicaciones de estudio
-
-
-
Bordeaux, Francia, 33076
- Aún no reclutando
- Pellegrin Hospital
-
Contacto:
- Anne Marie ROGUES, Professor
- Número de teléfono: +33 5 56 79 55 53
- Correo electrónico: anne-marie.rogues@chu-bordeaux.fr
-
Investigador principal:
- Anne Marie ROGUES, Professor
-
Dijon, Francia, 21079
- Aún no reclutando
- CHU Dijon
-
Contacto:
- Ludwig Serge AHO-GLELE, Professor
- Número de teléfono: +33 3 80 29 38 01
- Correo electrónico: ludwig.aho@chu-dijon.fr
-
Investigador principal:
- Ludwig Serge AHO-GLELE, professor
-
Lyon, Francia, 69003
- Reclutamiento
- Edouard Herriot Hospital
-
Contacto:
- Philippe VANHEMS, Professor
- Número de teléfono: +33 4 72 11 07 20
- Correo electrónico: Philippe.vanhems@chu-lyon.fr
-
Investigador principal:
- Philippe VANHEMS, Professor
-
Paris, Francia
- Aún no reclutando
- Saint Louis Hospital
-
Contacto:
- Nathalie DE CASTRO, Dr
- Número de teléfono: 01 42 49 48 20
- Correo electrónico: nathalie.de-castro@aphp.fr
-
Paris, Francia, 75877
- Aún no reclutando
- Bichat Hospital
-
Contacto:
- Solen KERNEIS, Professor
- Número de teléfono: +33 1 40 25 60 59
- Correo electrónico: solen.kerneis@aphp.fr
-
Investigador principal:
- Solen KERNEIS, professor
-
Paris, Francia, 75010
- Aún no reclutando
- Saint Louis Hospital
-
Contacto:
- Guillaume MELLON, Dr
- Número de teléfono: 01 42 49 44 97
- Correo electrónico: guillaume.mellon@aphp.fr
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults> 18 years old
- Hospitalized patient or health care professionals presenting an ILI on admission or during the stay, meeting the following definition: fever greater than 37.8° C in the absence of taking antipyretics and/or cough or pharyngeal pain.
- Signed consent form
Exclusion Criteria:
- Pregnant, parturient or breastfeeding women
- individuals deprived of their liberty by a judicial or administrative decision
- Individuals subject to psychiatric care
- Individuals admitted to a health or social establishment for purposes other than research
- Individuals under a legal protection measure (guardianship, curatorship)
- Individuals not affiliated to a social security insurance
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Patients hospitalized in participating services for more than 24h
Patients hospitalized for more than 24 hours in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) on admission or during hospital stay are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF. |
Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant. questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode. |
|
Otro: Volunteered health care professionals
Volunteered health care professionals in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF |
Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant. questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of hospital-acquired respiratory viral infections
Periodo de tiempo: At inclusion
|
The primary endpoint will be evaluated by calculating the incidence of hospital-acquired respiratory viral infections overall and by type of virus (influenza, COVID-19, RSV) during the surveillance period. incidence rate will be estimated by the ration of number of incident cases over the study period to the cumulative observation time (in person-weeks) of hospitalized patients. Incidence density will be estimated by the ratio of number of incident cases during successive weekly observation periods to the cumulative observation times calculated over the same periods. |
At inclusion
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Atributos de la enfermedad
- Infecciones del Tracto Respiratorio
- Infecciones
- Infecciones por Orthomyxoviridae
- Infecciones por virus de ARN
- Enfermedades virales
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Neumonía Viral
- Neumonía
- Infecciones por coronavirus
- Infecciones por coronaviridae
- Infecciones por Nidovirales
- Enfermedad iatrogénica
- Condiciones Patológicas, Signos y Síntomas
- COVID-19
- Influenza Humana
- Infección cruzada
- Calidad, acceso y evaluación de la atención médica
- Técnicas de investigación
- Métodos epidemiológicos
- Recopilación de datos
- Mecanismos de evaluación de atención médica
- Calidad de la atención médica
- Salud pública
- Medio ambiente y salud pública
- Encuestas y cuestionarios
Otros números de identificación del estudio
- 69HCL23_1091
- 2024-A01267-40 (Otro identificador: ID-RCB)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .